期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Development and validation of m6A RNA methylation regulatorsbased signature in lung adenocarcinoma
1
作者 Wei Guo Qi-Lin Huai +7 位作者 si-jin sun Lei Guo Xue-Min Xue Peng Song Jian-Ming Ying Yi-Bo Gao Shu-Geng Gao Jie He 《Chinese Medical Journal》 SCIE CAS CSCD 2021年第17期2128-2130,共3页
To the Editor:Primary lung cancer is the most commonly diagnosed type ofmalignant tumor and is the leading cause of cancer deathworldwide.Non-small cell lung cancer(NSCLC)makes up 80%to 85%of the overall incidents of ... To the Editor:Primary lung cancer is the most commonly diagnosed type ofmalignant tumor and is the leading cause of cancer deathworldwide.Non-small cell lung cancer(NSCLC)makes up 80%to 85%of the overall incidents of primary lung cancer and is classified into two distinct histological subtypes:lung adenocarcinoma(LUAD)and lung squamous cell carcinoma(LUSC).LUAD constitutes nearly 30%to 35%of all primary lung cancer cases,and the recurrence of it seems to be increasing in most countries.[1]As a prevalent mRNA internal modification,N6-methyladenosine(m6A)methylation modification is of great significance for triggering the development of cancer and can be used as a cancer-promoting factor in many cancers.[2,3]In this study,we aim to develop an m6A RNA methylation regulators-premised prognostic signature for LUAD patients. 展开更多
关键词 LUNG ADENOCARCINOMA SIGNATURE
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部